share_log

和黃醫藥：自願性公告－和黃醫藥宣佈沃瑞沙 (賽沃替尼/savolitinib) 按現行條款成功續約中國國家醫保藥品目錄

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HKEX ·  Nov 28 05:05

Summary by Moomoo AI

和黃醫藥於2024年11月28日宣佈，沃瑞沙®（賽沃替尼）成功續約中國國家醫保藥品目錄，將自2025年1月1日起生效。沃瑞沙®是一種強效、高選擇性的口服MET酪氨酸激酶抑制劑，於2021年6月在中國獲附條件批准，用於治療特定的MET外顯子14跳躍突變的非小細胞肺癌患者。此舉將有助於提高藥物的可負擔性，並繼續支持中國肺癌患者的治療。\\n沃瑞沙®於2023年3月1日首次納入醫保藥品目錄，並在此次續約中維持現行兩年期協議相同的條款。中國政府重視改善人民群眾用藥的可負擔性，基本醫療保險參保人數達13.3億，參保率穩定在95%左右。醫保藥品目錄每年調整，創新藥物每兩年續約，國家醫保局召集專家網絡對藥物...展開全部
和黃醫藥於2024年11月28日宣佈，沃瑞沙®（賽沃替尼）成功續約中國國家醫保藥品目錄，將自2025年1月1日起生效。沃瑞沙®是一種強效、高選擇性的口服MET酪氨酸激酶抑制劑，於2021年6月在中國獲附條件批准，用於治療特定的MET外顯子14跳躍突變的非小細胞肺癌患者。此舉將有助於提高藥物的可負擔性，並繼續支持中國肺癌患者的治療。\\n沃瑞沙®於2023年3月1日首次納入醫保藥品目錄，並在此次續約中維持現行兩年期協議相同的條款。中國政府重視改善人民群眾用藥的可負擔性，基本醫療保險參保人數達13.3億，參保率穩定在95%左右。醫保藥品目錄每年調整，創新藥物每兩年續約，國家醫保局召集專家網絡對藥物進行更新和調整。\\n沃瑞沙®由和黃醫藥與阿斯利康聯合開發，並由阿斯利康負責商業化。該藥物在中國獲批用於治療接受全身性治療後疾病進展或無法接受化療的MET外顯子14跳躍突變的非小細胞肺癌患者。和黃醫藥致力於將自主發現的抗腫瘤候選藥物帶向全球患者，並在中國、美國、歐洲和日本獲得批准。
hutchmed announced on November 28, 2024 that Vizimpro® (dacomitinib) has successfully renewed its listing on the China National Reimbursement Drug List, effective from January 1, 2025. Vizimpro® is a potent, highly selective oral MET tyrosine kinase inhibitor. It was conditionally approved in China in June 2021 for the treatment of specific non-small cell lung cancer patients with MET exon 14 skipping mutations. This move will help improve the affordability of the medication and continue to support the treatment of lung cancer patients in China. Vizimpro® was first included in the reimbursement drug list on March 1, 2023, and the terms of the current two-year agreement remain the same in this renewal. The Chinese government emphasizes improving the affordability of medications for the people. The number of...Show More
hutchmed announced on November 28, 2024 that Vizimpro® (dacomitinib) has successfully renewed its listing on the China National Reimbursement Drug List, effective from January 1, 2025. Vizimpro® is a potent, highly selective oral MET tyrosine kinase inhibitor. It was conditionally approved in China in June 2021 for the treatment of specific non-small cell lung cancer patients with MET exon 14 skipping mutations. This move will help improve the affordability of the medication and continue to support the treatment of lung cancer patients in China. Vizimpro® was first included in the reimbursement drug list on March 1, 2023, and the terms of the current two-year agreement remain the same in this renewal. The Chinese government emphasizes improving the affordability of medications for the people. The number of basic medical insurance participants has reached 1.33 billion, with an enrollment rate stable at around 95%. The reimbursement drug list is adjusted annually, with innovative drugs renewed every two years. The National Medical Insurance Administration convenes an expert network to update and adjust medications. Vizimpro® is jointly developed by hutchmed and AstraZeneca, with AstraZeneca responsible for commercialization. The drug is approved in China for the treatment of non-small cell lung cancer patients with MET exon 14 skipping mutations who have progressed after systemic treatment or are unable to undergo chemotherapy. hutchmed is committed to bringing its independently discovered anti-tumor candidate drugs to global patients, with approvals in China, the USA, Europe, and Japan.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated